Oct 15 (Reuters) - AbbVie Inc (NYSE:ABBV) ABBV.N :
* HEALTH CANADA APPROVES LABEL UPDATE FOR ABBVIE'S HUMIRA® (ADALIMUMAB) SUPPORTING POTENTIAL FOR USE DURING BREASTFEEDING AND USE DURING PREGNANCY IF CLEARLY NEEDED
* ABBVIE - UPDATED LABEL PROVIDES GUIDANCE HUMIRA USE CAN BE CONSIDERED WHILE BREASTFEEDING & SHOULD ONLY BE USED DURING PREGNANCY IF CLEARLY NEEDED